For T1b or T2a NSCLC cancer, approached with SABR, should chemotherapy be considered in the adjuvant setting?

It is not standard of care to give adjuvant chemotherapy in IA NSCLC.

It can be considered in certain situations of stage IB, although there is no strong prospective data. The group with > 4 cm size tumars had some benefit in an unplanned subgroup analysis of the CALGB study. If other risk factors be...

From the multiple phase III trials of postop adjuvant therapy for NSCLC, one could reasonably extrapolate that a policy to give chemo to all stage IB pts after SAbR does not make sense. Yes, one can consider the factors listed by @Dr. First Last such as size ≥ 4cm to select a population with a highe...